Serplulimab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Serplulimab is a monoclonal antibody used in the treatment of certain types of cancer. It is designed to target and inhibit the PD-1 (programmed cell death protein 1) pathway, which is a mechanism that tumors use to evade the immune system. By blocking this pathway, serplulimab helps to restore the immune system's ability to recognize and destroy cancer cells.
Mechanism of Action[edit | edit source]
Serplulimab is an immune checkpoint inhibitor. It binds to the PD-1 receptor on T-cells, preventing its interaction with PD-L1 and PD-L2 ligands found on tumor cells and other cells in the tumor microenvironment. This blockade releases the "brakes" on the immune system, allowing T-cells to attack and kill cancer cells more effectively.
Clinical Applications[edit | edit source]
Serplulimab is primarily used in the treatment of non-small cell lung cancer (NSCLC) and other malignancies that express PD-L1. Clinical trials have demonstrated its efficacy in improving overall survival and progression-free survival in patients with advanced cancers.
Side Effects[edit | edit source]
As with other immune checkpoint inhibitors, serplulimab can cause immune-related adverse events (irAEs) due to increased immune activity. Common side effects include fatigue, rash, diarrhea, and endocrinopathies such as hypothyroidism. More severe irAEs can affect the lungs (pneumonitis), liver (hepatitis), and other organs.
Research and Development[edit | edit source]
Serplulimab is currently undergoing various clinical trials to evaluate its efficacy in combination with other therapies, such as chemotherapy and other immunotherapies. Ongoing research aims to expand its use to other types of cancer and to identify biomarkers that predict response to treatment.
Regulatory Status[edit | edit source]
Serplulimab has been approved for use in several countries for specific cancer indications. Its approval status may vary based on the results of ongoing clinical trials and regulatory reviews.
Also see[edit | edit source]
- Monoclonal antibody therapy
- Immune checkpoint inhibitors
- Cancer immunotherapy
- PD-1 and PD-L1 inhibitors
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
